Compare Davita Inc (DVA) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Gigacloud Technology Inc — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Gigacloud Technology Inc trades at $35.78 (market cap $1.32B). The key difference: Davita Inc is far larger — about 11.3× Gigacloud Technology Inc's market cap, and Davita Inc is trading nearer its 52-week high, Gigacloud Technology Inc nearer its low. Which is the better fit depends on your goals.
| DVA | GCT | |
|---|---|---|
Market Cap | $14.92B | $1.32B |
Sector | Health | Technology |
52-Week High | $235.71 | $51.80 |
52-Week Low | $103.87 | $20.26 |
Enterprise Value | $27.47B | $1.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
GigaCloud Technology (GCT) trades at $35.40, up 2.88% today, showing strong momentum with consistent earnings beats and robust fundamentals. The stock exhibits a bullish technical signal with key resistance at $36 and support at $34. Recent financials reveal impressive profitability with a 10.77% net income margin and 32.14% ROE, while valuation ratios like P/E of 8.96 suggest potential undervaluation. Positive media coverage highlights growth prospects, including recognition as a 'World Growth Leader' by TIME in June 2026.
Outlook remains positive due to earnings growth and operational efficiency, but risks include market volatility and competitive pressures. Analyst consensus is bullish with 67% buy ratings, supporting upside potential if execution continues. Investors should weigh strong cash flow against sector-specific headwinds for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
